Medical Research
GeoVax CEO to Present at ROTH Healthcare Conference, Highlighting Vaccine and Cancer Therapy Pipeline
GeoVax Labs' participation in the ROTH Healthcare Opportunities Conference provides investors with insights into the company's advancing vaccine and cancer therapy pipeline, including progress on Mpox, COVID-19 vaccines, and oncology treatments.
Stanford Study Shows Pulsed Shortwave Therapy Provides Sustained Pain Relief for Thumb Arthritis
A Stanford University clinical trial demonstrates that pulsed shortwave therapy offers lasting pain relief for thumb arthritis, potentially providing a safe, drug-free alternative to current limited treatment options for millions of affected adults.
Boston University Professor Honored with Prestigious Mentorship Award for Cardiovascular Research Training
Dr. Emelia J. Benjamin of Boston University receives the 2025 Eugene Braunwald Academic Mentorship Award for her extensive work mentoring the next generation of cardiovascular researchers and clinicians, highlighting the critical role of mentorship in advancing cardiovascular science.
Cardiovascular Complications Affect 1 in 7 Pregnancies as Risk Factors Rise Sharply
New research reveals cardiovascular complications impact 15% of pregnancies, driven by increasing rates of obesity, hypertension, diabetes and high cholesterol over the past two decades.
OHSU Receives $6.7M NIH Grant to Study Cannabis Effects in HIV-Positive Pregnant Women
Oregon Health and Science University researchers secured substantial federal funding to investigate marijuana's impact on HIV-positive pregnant women, addressing critical gaps in medical cannabis research and maternal health.
Sapu Nano Receives Australian Ethics Approval for Breast Cancer Drug Trial
Sapu Nano's Sapu003, an injectable form of Everolimus using proprietary nanoparticle technology, has received HREC approval for human clinical trials in Australia, potentially offering more effective breast cancer treatment through improved drug delivery.
Quantum BioPharma Appoints Leading MS Expert Dr. Jack Antel as Clinical Advisor for Lucid-MS Development
Quantum BioPharma has strengthened its multiple sclerosis program by appointing renowned neurologist Dr. Jack Antel to guide the clinical development of Lucid-21-302 as the investigational drug advances toward Phase 2 trials.
NYU's Judith Hochman to Receive 2025 Research Achievement Award for Transformative Cardiology Research
Dr. Judith Hochman's recognition by the American Heart Association highlights her pivotal clinical trials that have reshaped global cardiology guidelines and improved patient outcomes in ischemic heart disease.
National Survey Reveals Nearly Half of Americans Suffer From Unexplained Pain and Illness
A new national survey shows that 48% of Americans experience unexplained chronic pain or illness, highlighting the urgent need for greater awareness and access to neuroplastic treatments that could transform healthcare outcomes.
Soligenix Expands European Medical Advisory Board to Advance Cutaneous T-Cell Lymphoma Treatment
Soligenix Inc. has expanded its European Medical Advisory Board to guide the confirmatory Phase 3 trial of HyBryte for early-stage cutaneous T-cell lymphoma, strengthening European engagement ahead of potential commercialization of this novel photodynamic therapy.
Scorpion Venom Compound Shows Promise in Brain Cancer Treatment Research
Researchers are exploring how scorpion venom compounds could revolutionize brain tumor treatment by helping the immune system target glioblastoma more effectively.
Soligenix Advances Psoriasis Treatment Trial with Promising Early Results
Soligenix is progressing its SGX302 psoriasis treatment through clinical trials, offering potential for a new therapeutic option for millions affected by the autoimmune skin condition.
UCSF Researcher Receives Prestigious Award for Study on Postpartum Cardiovascular Care Disparities
Dr. Megan McLaughlin's award-winning research reveals significant gaps in postpartum cardiovascular care for women with pregnancy-related hypertension, highlighting critical opportunities to improve long-term heart health in high-risk populations.
New Research Reveals Menopause's Significant Impact on Multiple Sclerosis Symptoms and Comorbidities
Groundbreaking research presented at the ECTRIMS 2025 conference demonstrates how hormonal changes during menopause influence both initial symptoms and comorbidities in women with multiple sclerosis, potentially guiding future treatment development.
Clene's CNM-Au8 Shows Promising Brain Energy Improvements in Multiple Sclerosis Patients
Clene Inc. presented positive trial results demonstrating that its investigational therapy CNM-Au8 significantly improved brain energy metabolism in multiple sclerosis patients, potentially offering a new approach to slowing disease progression by addressing underlying bioenergetic failure.
Soligenix Advances HyBryte Treatment for Cutaneous T-Cell Lymphoma with FLASH Trial Results
Soligenix is strengthening its position in CTCL treatment through promising results from its HyBryte FLASH studies, representing significant progress toward establishing a new standard of care in an underserved therapeutic area.
Oncotelic's Joint Venture Sapu Nano Receives Approval for Phase 1 Trial of Injectable Everolimus for Breast Cancer
Sapu Nano's approval to begin Phase 1 clinical trials for an injectable version of Everolimus represents a potential breakthrough in breast cancer treatment by enabling full drug absorption compared to the oral version's limited 10% bioavailability.
Circular DNA Fragments Identified as Key Factor in Glioblastoma Lethality
International researchers have discovered that rogue circular DNA fragments operating independently from chromosomes may explain why glioblastoma remains so deadly despite medical advances, potentially opening new treatment pathways.
MUSC Professor Daniel Lackland to Receive 2025 Population Research Prize for Hypertension Research
Dr. Daniel Lackland's recognition by the American Heart Association highlights the critical importance of population-level research in addressing cardiovascular health disparities and improving hypertension treatment strategies globally.
Psychological Distress After Heart Attack Linked to Increased Risk of Future Cardiac Events
New research reveals that psychological distress affects up to 50% of heart attack survivors and increases the risk of future cardiac events by 1.3 to 2 times, highlighting the critical need for integrated mental health care in cardiac recovery.
Soligenix Advances Oral Mucositis Treatment SGX942 with Combined Clinical Data Analysis
Soligenix is leveraging positive phase 2 and 3 clinical data to design a second pivotal trial for SGX942, addressing the critical unmet medical need for oral mucositis treatment in cancer patients.
Lantern Pharma Completes Japan Enrollment in Phase 2 Trial for Never-Smoker Lung Cancer Treatment
Lantern Pharma has achieved targeted patient enrollment in Japan for its Phase 2 HARMONIC trial evaluating LP-300 in never-smoker non-small cell lung cancer patients, marking significant progress in addressing an underserved population with high unmet medical need.
UCLA Researchers Awarded $2M Grant for MRI-Guided Cancer Radiation Therapy Study
UCLA Health receives a $2 million grant from ViewRay Systems to advance research on MRI-guided radiation therapy for targeted cancer treatment, highlighting growing investment in precision oncology technologies.
Plus Therapeutics Subsidiary CNSide Diagnostics Achieves CLIA Accreditation for CNS Cancer Testing Lab
CNSide Diagnostics has received CMS accreditation for its clinical laboratory, enabling broader patient access and insurance coverage for its cerebrospinal fluid assay platform used in central nervous system cancer detection.
Dietary Protein Restriction May Enhance Glioblastoma Treatment Efficacy, Study Finds
University of Michigan research indicates that low-protein diets combined with serine-free protein shakes could improve chemotherapy and radiation outcomes for glioblastoma patients by making tumors more vulnerable to treatment.
GeoVax's CM04S1 Vaccine Shows Promise for Immunocompromised Patients in Phase 2 Trials
GeoVax Labs' next-generation COVID-19 vaccine candidate demonstrates superior immune responses in immunocompromised patients compared to mRNA vaccines, potentially addressing critical gaps in current vaccination strategies.
Cancer Patients Face Nutritional Challenges During Treatment as Companies Develop New Therapies
Cancer patients struggle with increased nutritional needs during treatment while facing eating difficulties, highlighting the importance of dietary management alongside medical advancements.
Clene's CNM-Au8 Shows Promise in Addressing Cellular Dysfunction in Parkinson's Disease
Clene Inc.'s investigational therapy CNM-Au8 demonstrates potential to improve mitochondrial health and reduce inflammation in Parkinson's disease models, offering new hope for addressing the underlying cellular mechanisms driving neurodegeneration.
Oncotelic Therapeutics Featured in Editorial Highlighting Innovative Cancer and Rare Disease Pipeline
Oncotelic Therapeutics' inclusion in a NetworkNewsWire editorial underscores the company's growing prominence in developing RNA-based and immunotherapy treatments for aggressive cancers and pediatric rare diseases, positioning it for significant market growth.
GeoVax's Multi-Antigen COVID-19 Vaccine Shows Superior Immune Response in CLL Patients Compared to mRNA Vaccines
GeoVax's GEO-CM04S1 vaccine demonstrated significantly better immune response in chronic lymphocytic leukemia patients than standard mRNA vaccines, addressing a critical unmet need in immunocompromised populations.